Top Markets
#1 Nesa Nesa +820.50%
#2 Cortex Cortex +68.91%
#3 Kinesis Silver Kinesis Silver +57.40%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.66%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +20.46%
#8 OpenEden OpenEden +19.61%
#9 Palladium Network Palladium Network +18.94%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Jyong Biotech Ltd. Ordinary Shares Jyong Biotech Ltd. Ordinary Shares

Jyong Biotech Ltd. Ordinary Shares

MENS
Rank in Stocks #19255
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the... Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Share Price
$2.22
Last synced: 2026-08-25
Market Cap
$168.64M
Change (1 day)
-0.09%
Change (1 year)
-95.58%
Country
TW
Trade Jyong Biotech Ltd. Ordinary Shares (MENS)

Category

Healthcare
Revenue for Jyong Biotech Ltd. Ordinary Shares (MENS)
Revenue in Aug 2026 TTM: 0
According to Jyong Biotech Ltd. Ordinary Shares latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jyong Biotech Ltd. Ordinary Shares from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH